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Are we ready for a randomized trial of valproic acid in newly diagnosed glioblastoma? 
 
Valproic acid is a well-established antiepileptic drug with a still enigmatic mode of 
action. The drug acid has been proposed to work by inhibiting various ion channels 
or promoting GABA signaling, moreover, it also exhibits pharmacodynamic properties 
likely to be unrelated to its antiepileptic activity, including inhibition of histone 
deacetylases (HDAC). In contrast to classical enzyme-inducing antiepileptic drugs, 
valproic acid is a multiple enzyme inhibitor, targeting amongst others UDP-
glucuronosyltransferase, epoxide hydroxylase and CYP2C coenzymes.1 
The first therapeutic applications of valproic acid in neurooncology beyond its role as 
an antiepileptic drug stem from the pediatric literature where valproic acid was 
assumed to induce differentiation of tumor cells. In recent years a growing list of 
retrospective analyses have indicated that glioma patients exposed to valproic acid 
have a superior outcome,2-4 including an analysis of patients treated within the 
registration trial for temozolomide in newly diagnosed glioblastoma.5 
In the present issue of Neuro-Oncology, De Wit-Kerkhof and colleagues studied the 
effect of valproic acid on seizure control and survival in patients with glioblastoma 
diagnosed and treated from July 1999 until September 2011.6 Of 291 patients, 181 
had seizures and were treated with valproic acid or levetiracetam or their combination 
and had a minimum follow-up of six months; 108 of these patients were treated with 
temozolomide and valproic acid for at least 3 months. The analysis of efficacy of 
antiepileptic drug treatment was limited to patients with a minimum follow up of 6 
months. For the analysis of survival effects of antiepileptic drug treatment, a minimum 
duration of 3 months of the combination of temozolomide and valproic acid was 
required. Both these aspects of the study design introduce a significant bias that 
needs to be considered when analysing the data. This is because these measures 
select for favourable course patients since progression would have led to either 
discontinuation of temozolomide, or possibly increased seizure activity and a change 
of the antiepileptic drug regimen, or rapid deterioration incompatible with further 
follow-up, or combinations thereof. 
Freedom from seizures was achieved with monotherapy in 41 of 100 patients treated 
initially with valproic acid (41%) and in 16 of 37 patients treated initially with 
levetiracetam (43.3%). Using either drug alone or in combination, 89 of 116 patients 
(76.7%) became seizure-free overall.  
For the survival studies the authors then proceeded to analyse 108 patients treated 
with valproic acid and temozolomide for at least 3 months. They were compared to 
57 patients treated with valproic acid for less than 3 months or another antiepileptic 
drug or no antiepileptic drug at all. These two groups were reported to be balanced 
regarding major patient characteristics including O6-methylguanine DNA 
methyltransferase (MGMT) promoter methylation status. Patients treated with 
valproic acid had a longer medium survival of 69 weeks (95% CI 61.7-67.3) 
compared with 61 weeks (95% CI, 52.5-69.5) in those not receiving valproic acid for 
3 months (HR 0.63, 95% CI 0.43-0.92) (p=0.016). The difference in progression-free 
survival between these groups was not significant (p=0.06). Surprisingly, neither 
extent of resection nor MGMT promoter methylation status, but only age and valproic 
acid treatment were significant prognostic factors on multivariate analysis in this 
subgroup of 165 patients (Table 3). 
While this analysis adds to the literature supporting a disease course-modifying role 
for valproic acid in glioblastoma, it has several limitations: the patients were collected 
over a long time period, MGMT promoter methylation data were available for less 
than half of the patients, and the inclusion criteria for analysis in the subpopulations 
introduce a bias as outlined above that is difficult to estimate but likely has an impact. 
This is illustrated by the fact that neither complete resection nor MGMT status 
retained prognostic significance on multivariate analysis in Table 3. Besides small 
numbers, notably for MGMT where approximately half of the patients had no status 
available, this striking observation is most likely explained by the fact that poor 
prognosis patients had a priori been eliminated from this analysis by its very design. 
This is corroborated by the data shown in Table 4 which show a rate of total 
resections in the range of 80%, which is double the rate usually reported, and a 
relatively higher rate of MGMT promoter-methylated patients in the valproic acid 
group. Interestingly, as in the analysis from the EORTC NCIC-trial,5 valproic acid 
given early on in the disease course had no effect on progression-free survival, but 
only an effect on overall survival. This is difficult to explain on a biological basis 
unless we assume once more that we are not able to reliably measure progression or 
that valproic acid pretreatment primes glioblastomas for favourable responses to 
salvage therapies. 
The present study supports the evidence of a survival-promoting effect of valproic 
acid in glioblastoma. However, all the analyses supporting this view carry inherent 
limitations: they are all retrospective, there was commonly no in depth study of 
duration and intensity of exposure to the drug, and the number of patients in each of 
these series was relatively small. In the absence of promising pharmacological 
agents in the treatment of newly diagnosed glioblastoma, it is obvious that there is 
now significant interest in exploring a possible inclusion of valproic acid into the 
standards of care for newly diagnosed glioblastoma.  
This would, however, require a randomized trial which is going to be a rather 
expensive, large trial if conducted in the US or Europe today, without a commercial 
sponsor to support such an endeavor. This does not mean that such a trial should 
not be done if the scientific community believes that it should be done. However, 
before such a clinical trial concept is moved forward, it seems to be mandatory to 
make use of contemporary prospective clinical trial populations where comedication 
has been captured with precision, including RTOG0525, CENTRIC and AVAGlio. A 
joint analysis of these patient populations exploring the potential impact of 
comedication with valproic acid should guide us in determining whether the next step, 
a randomized phase II trial of valproic acid in newly diagnosed glioblastoma, should 
be undertaken or not. 
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